Clinical Trial Applications - Approved: Filter, Search, and view applications
| # | Protocol No | Study Title | Investigator(s) & Site(s) | Date Approved | |
|---|---|---|---|---|---|
141. |
ECCT/21/11/05 | SOLIDARITY TRIAL PLUS An international randomised trial of additional treatments for COVID-19 in hospitalised patients who are all receiving the local standard of care |
Principal Investigator(s) 1. loice Ombajo Site(s) in Kenya 1. KENYATTA NATIONAL HOSPITAL SITE (Nairobi City county) 2. The Nairobi Hospital (Nairobi City county) |
13-01-2022 |
View |
142. |
ECCT/20/04/01 | Solidarity An international randomised trial of additional treatments for COVID-19 in hospitalised patients who are all receiving the local standard of care |
Principal Investigator(s) 1. Loice Achieng Ombajo Site(s) in Kenya 1. Kilifi Kemri-Wellcome (Kilifi county) 2. Kenya National Hospital (Nairobi City county) 3. Coast PGH (Mombasa county) 4. The Nairobi Hospital (Nairobi City county) 5. Aga Khan University Hospital (Nairobi City county) 6. Moi Teahing and Referal Hospital (Uasin Gishu county) 7. Kenyatta University teaching research and referal hospital (Kiambu county) |
22-06-2020 |
View |
143. |
ECCT/23/07/04 | PRAISE An Adaptive, Randomized, Placebo-controlled, Double-blind, Multi-center Study of Oral FT-4202, a Pyruvate Kinase Activator in Patients with Sickle Cell Disease (PRAISE) |
Principal Investigator(s) 1. Dr. Janet Oyieko Site(s) in Kenya 1. Kondele Children\'s Hospital Center for Clinical Research (CCR), (Kisumu county) 2. Gertrude\'s Children Hospital (Nairobi City county) 3. KEMRI/CRDR Kemri Clinical Research Annex (Siaya county) |
28-08-2023 |
View |
144. |
ECCT/23/08/02 | PRAISE An Adaptive, Randomized, Placebo-controlled, Double-blind, Multi-center Study of Oral FT-4202, a Pyruvate Kinase Activator in Patients with Sickle Cell Disease (PRAISE) |
Principal Investigator(s) 1. Nduba Videlis Site(s) in Kenya 1. Getrudes Children Hospital (Nairobi City county) 2. KEMRI/CRDR (Siaya county) 3. Kombewa CRC (Kisumu county) 4. Kondele Childrens Hospital (Kisumu county) |
18-10-2023 |
View |
145. |
ECCT/23/01/02 | PRAISE An Adaptive, Randomized, Placebo-controlled, Double-blind, Multi-center Study of Oral FT-4202, a Pyruvate Kinase Activator in Patients with Sickle Cell Disease (PRAISE) |
Principal Investigator(s) 1. Ogutu Bernhards Ragama Site(s) in Kenya 1. Kondele Children\'s Hospital Center for Clinical Research (CCR), (Kisumu county) 2. Gertrude\'s Children Hospital (Nairobi City county) 3. KEMRI/CRDR Kemri Clinical Research Annex Siaya County Referral Hospital Grounds, (Siaya county) 4. Kombewa CRC (Kisumu county) |
24-05-2023 |
View |
146. |
ECCT/23/01/03 | PRAISE An Adaptive, Randomized, Placebo-controlled, Double-blind, Multi-center Study of Oral FT-4202, a Pyruvate Kinase Activator in Patients with Sickle Cell Disease (PRAISE) |
Principal Investigator(s) 1. Githanga Githanga Nyokabi Site(s) in Kenya 1. Gertrude\'s Children Hospital (Nairobi City county) 2. Kondele Children\'s Hospital Center for Clinical Research (CCR), (Kisumu county) 3. KEMRI/CRDR Kemri Clinical Research Annex Siaya County Referral Hospital Grounds (Siaya county) 4. Kombewa CRC (Kisumu county) |
19-06-2023 |
View |
147. |
ECCT/23/02/02 | KARISMA An adaptive, randomized, active-controlled, open-label, sequential cohort, multicenter study to evaluate the efficacy, safety, tolerability, and pharmacokinetics of intravenous cipargamin (KAE609) in adult and pediatric participants with severe Plasmodium falciparum malaria(KARISMA – KAE609’s Role in Severe Malaria) |
Principal Investigator(s) 1. Simon Kariuki Site(s) in Kenya KEMRI-CGHR, |
01-06-2023 |
View |
148. |
ECCT/21/05/03 | Adapt Out COVID Adaptive Platform Treatment trial for Outpatients with COVID-19 |
Principal Investigator(s) 1. Kawango Agot Site(s) in Kenya 1. Kenya Impact and Research Development Organization (K-IRDO) (Kisumu county) 2. KEMRI WALTER REED (Kericho county) 3. MOI UNIVERSITY CLINICAL RESEARCH CENTRE (Uasin Gishu county) 4. Kenya Medical Research Institute (Kisumu county) |
28-07-2021 |
View |
149. |
ECCT/21/06/01 | ACTIV-2/A5401 ACTIV-2/A5401 "Adaptive Platform Treatment Trial for Outpatients with COVID-19" (Adapt Out COVID)_ |
Principal Investigator(s) 1. Charles Meja Kwobah Site(s) in Kenya 1. Moi University Clinical Research Centre (Uasin Gishu county) 2. KEMRI Walter Reed Project (Kericho county) |
01-11-2021 |
View |
150. |
ECCT/14/10/02 | Acronymn: CRASH-3 Short Title: Clinical Randomisation of an Antifibrinolytic in Significant Head Injury Full Title: Tranexamic acid for the treatment of significant traumatic brain injury: an international randomised, double blind placebo controlled trial ISRCTN15088122 ClinicalTrials.gov ID: NCT01402882 |
Principal Investigator(s) 1. Kiboi Githinji Julius 2. Dullo Michael 3. Lallet Tasneem Essaji Site(s) in Kenya 1. Kenyatta National Hospital (Nairobi City county) 2. Kitui District Hospital (Kitui county) 3. The Nairobi Hospital (Nairobi City county) |
05-02-2015 |
View |